European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies

Objectives To develop recommendations for monitoring patients with systemic lupus erythematosus (SLE) in clinical practice and observational studies and to develop a standardised core set of variables to monitor SLE. Methods We followed the European League Against Rheumatism (EULAR) standardised procedures for guideline development. The following techniques were applied: nominal groups, Delphi surveys for prioritisation, small group discussion, systematic literature review and two Delphi rounds to obtain agreement. The panel included rheumatologists, internists, dermatologists, a nephrologist and an expert related to national research agencies. The level of evidence and grading of recommendations were determined according to the Levels of Evidence and Grades of Recommendations of the Oxford Centre for Evidence-Based Medicine. Results A total of 10 recommendations have been developed, covering the following aspects: patient assessment, cardiovascular risk factors, other risk factors (osteoporosis, cancer), infection risk (screening, vaccination, monitoring), frequency of assessments, laboratory tests, mucocutaneous involvement, kidney monitoring, neuropsychological manifestations and ophthalmology assessment. A ‘core set’ of minimal variables for the assessment and monitoring of patients with SLE in clinical practice was developed that included some of the recommendations. In addition to the recommendations, indications for specific organ assessments that were viewed as part of good clinical practice were discussed and included in the flow chart. Conclusions A set of recommendations for monitoring patients with SLE in routine clinical practice has been developed. The use of a standardised core set to monitor patients with SLE should facilitate clinical practice, as well as the quality control of care for patients with SLE, and the collection and comparison of data in observational studies.

[1]  W. Scherbaum,et al.  Osteoporosis screening in systemic lupus erythematosus: impact of disease duration and organ damage , 2001, Lupus.

[2]  Prevalence and factors associated with dyslipoproteinemias in Brazilian systemic lupus erythematosus patients , 2008, Rheumatology International.

[3]  M. Petri.  Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. , 1995, Arthritis care and research : the official journal of the Arthritis Health Professions Association.

[4]  G. Schiffman,et al.  Specific antibody response after in vivo antigenic stimulation in systemic lupus erythematosus. , 1984, The Journal of rheumatology.

[5]  S. Quaglini,et al.  Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  Caroline Gordon,et al.  Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. , 2006, Arthritis and rheumatism.

[7]  A. Hingorani,et al.  Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. , 2004, Rheumatology.

[8]  I. Bruce,et al.  Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. , 2003, Arthritis and rheumatism.

[9]  P. Chan,et al.  Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. , 2004, Arthritis and rheumatism.

[10]  L. Magder,et al.  A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. , 2001, Arthritis and rheumatism.

[11]  V. Joshi,et al.  Tuberculosis in patients with systemic lupus erythematosus. , 1998, The Journal of the Association of Physicians of India.

[12]  C. Gordon,et al.  Definition and treatment of lupus flares measured by the BILAG index. , 2003, Rheumatology.

[13]  D. Alarcón-Segovia,et al.  Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus. , 1994, The Journal of rheumatology.

[14]  J. Sibley,et al.  Systemic lupus erythematosus and the risk of malignancy , 2001, Lupus.

[15]  D. Isenberg,et al.  C-reactive protein in sera from patients with systemic lupus erythematosus. , 1981, The Journal of rheumatology.

[16]  G. Illei,et al.  Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. , 2002, Arthritis and rheumatism.

[17]  P. Raggi,et al.  High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors , 2006, Annals of the rheumatic diseases.

[18]  D. Solomon,et al.  Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. , 2002, Arthritis and rheumatism.

[19]  J. Reveille,et al.  Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XL II: factors predictive of new or worsening proteinuria. , 2006, Rheumatology.

[20]  D A Isenberg,et al.  The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. , 1993, The Quarterly journal of medicine.

[21]  M. Marmor,et al.  Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. , 2002, Ophthalmology.

[22]  E. M. Dalmarco,et al.  HPV detection and genotyping as an earlier approach in cervical cancer screening of the female genital tract. , 2008, Clinical and experimental obstetrics & gynecology.

[23]  E. Hachulla,et al.  Longitudinal determination of antiphospholipid antibodies in lupus patients without previous manifestations of antiphospholipid syndrome. A prospective study. , 1999, The Journal of rheumatology.

[24]  D. Buskila,et al.  Hepatitis B and C viruses serology in patients with SLE , 1997, Lupus.

[25]  J. Harley,et al.  Development of Anti‐dsDNA Autoantibodies Prior to Clinical Diagnosis of Systemic Lupus Erythematosus , 2001, Scandinavian journal of immunology.

[26]  S. Bae,et al.  The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. , 2002, Clinical and experimental rheumatology.

[27]  F. Houssiau,et al.  Pneumococcal sepsis in patients with systemic lupus erythematosus , 2005, Lupus.

[28]  D. Gladman,et al.  Non-Hodgkin’s lymphoma in systemic lupus erythematosus , 2005, Annals of the rheumatic diseases.

[29]  M. Sticherling,et al.  Diagnostic approach and treatment of cutaneous lupus erythematosus , 2008, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[30]  I. Bruce,et al.  Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. , 2007, Arthritis and rheumatism.

[31]  F. Salaffi,et al.  Health-related quality of life in Italian patients with systemic lupus erythematosus. I. Relationship between physical and mental dimension and impact of age. , 2004, Rheumatology.

[32]  Petros P Sfikakis,et al.  The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. , 2003, Ophthalmology.

[33]  Y. Shoenfeld,et al.  Vaccination as an additional player in the mosaic of autoimmunity. , 2000, Clinical and experimental rheumatology.

[34]  Y. Shoenfeld,et al.  Infection, vaccines and other environmental triggers of autoimmunity , 2005, Autoimmunity.

[35]  L. Magder,et al.  Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. , 1994, The American journal of medicine.

[36]  J. Goo,et al.  Pulmonary tuberculosis in patients with systematic lupus erythematosus. , 1999, AJR. American journal of roentgenology.

[37]  R du Berger,et al.  The relationship between disease activity and expert physician's decision to start major treatment in active systemic lupus erythematosus: a decision aid for development of entry criteria for clinical trials. , 1998, The Journal of rheumatology.

[38]  J. Nolla,et al.  Loss of bone mineral density in premenopausal women with systemic lupus erythematosus. , 1995, Annals of the rheumatic diseases.

[39]  F. Salaffi,et al.  Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. , 2004, Rheumatology.

[40]  H. Peter,et al.  Association of IgA anti-dsDNA antibodies with vasculitis and disease activity in systemic lupus erythematosus , 1998, Rheumatology International.

[41]  H. Hashimoto,et al.  Risk Factors for Recurrent Thrombosis: Prospective Study of a Cohort of Japanese Systemic Lupus Erythematosus , 2005, Angiology.

[42]  D. Gladman,et al.  Accrual of organ damage over time in patients with systemic lupus erythematosus. , 2003, The Journal of rheumatology.

[43]  C. Lau,et al.  Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. , 2004, Arthritis and rheumatism.

[44]  D. Gladman,et al.  The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[45]  W. Blackwelder,et al.  Pneumococcal immunization in patients with systemic lupus erythematosus treated with immunosuppressives. , 1985, The Journal of rheumatology.

[46]  M. Urowitz,et al.  Anti-dsDNA and anti-Sm antibodies do not predict damage in systemic lupus erythematosus , 2006, Lupus.

[47]  M. Brózik,et al.  Diagnostic value of combined evaluation of neopterin and anti-DNA antibody levels for assessment of disease activity in systemic lupus erythematosus. , 2000, Clinical and experimental rheumatology.

[48]  Y. Shoenfeld,et al.  Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus , 2003, Annals of the rheumatic diseases.

[49]  J. Ager,et al.  Abnormal cervicovaginal cytology in women with lupus: a retrospective cohort study. , 2001, Gynecologic oncology.

[50]  J. Reveille,et al.  Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis , 2002, Lupus.

[51]  M. Boers,et al.  EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases , 2007, Annals of the rheumatic diseases.

[52]  E. Lewis,et al.  Value of a complete or partial remission in severe lupus nephritis. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[53]  J. Cuzick,et al.  Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older , 2009, International journal of cancer.

[54]  M. Lieberman,et al.  Antigen-specific antibody responses in lupus patients following immunization. , 1998, Arthritis and rheumatism.

[55]  N. Shemonsky,et al.  Acute lupus erythematosus (SLE) following polyvalent pneumococcal vaccine. , 1981, South Dakota journal of medicine.

[56]  V. Cheng,et al.  Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus. , 2006, QJM : monthly journal of the Association of Physicians.

[57]  L. Pasquier,et al.  Orphanet Journal of Rare Diseases , 2006 .

[58]  L. Magder,et al.  Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. , 2001, Arthritis and rheumatism.

[59]  G. Nuovo,et al.  The Utility of HPV In Situ Hybridization and the PAS Test in Improving the Specificity of the Diagnosis of CIN 1 , 2009, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[60]  M. López-Hoyos,et al.  Clinical disease activity and titers of anti-dsDNA antibodies measured by an automated immunofluorescence assay in patients with systemic lupus erythematosus , 2005, Lupus.

[61]  B. Tebbe.  Clinical course and prognosis of cutaneous lupus erythematosus. , 2004, Clinics in dermatology.

[62]  T. D. Du Clos,et al.  Studies of serum C-reactive protein in systemic lupus erythematosus. , 2005, The Journal of rheumatology.

[63]  M. Lockshin,et al.  Characteristics of high-titer IgG antiphospholipid antibody in systemic lupus erythematosus patients with and without fetal death. , 1990, Arthritis and rheumatism.

[64]  J. Setoain,et al.  The effect of systemic lupus erythematosus and long-term steroid therapy on bone mass in pre-menopausal women. , 1995, British journal of rheumatology.

[65]  G. Dunea,et al.  The prognosis of lupus nephritis in African-Americans: a retrospective analysis. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[66]  A. Piccoli,et al.  Long-term prognosis and causes of death in systemic lupus erythematosus. , 2006, The American journal of medicine.

[67]  F. Hugo,et al.  The association between the antiphospholipid antibody syndrome and neuropsychological impairment in SLE , 1999, Lupus.

[68]  B. Dijkmans,et al.  Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. , 2005, Arthritis and rheumatism.

[69]  T. Chan,et al.  Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy. , 2005, The Journal of rheumatology.

[70]  C. Qualls,et al.  Cigarette smoking and disease activity in systemic lupus erythematosus. , 2003, The Journal of rheumatology.

[71]  S. Giannini,et al.  High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. , 2006, Bone.

[72]  D A Isenberg,et al.  Development and initial validation of an updated version of the British Isles Lupus Assessment Group ’ s disease activity index for patients with systemic lupus erythematosus , 2005 .

[73]  D. Isenberg,et al.  Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus , 2004, Annals of the rheumatic diseases.

[74]  G. Hughes,et al.  Immunosuppressive therapy in lupus nephritis. , 1997, Clinical and experimental rheumatology.

[75]  C. Ohlsson,et al.  Prevalence and risk factors of osteoporosis in female SLE patients-extended report. , 2007, Rheumatology.

[76]  A. Todd-Pokropek,et al.  The Relationship of Anti‐DNA Antibody Idiotypes and Anti‐Cardiolipin Antibodies to Disease Activity in Systemic Lupus Erythematosus , 1986, Medicine.

[77]  J. Ablin,et al.  Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases. , 2007, Autoimmunity reviews.

[78]  M. Petri,et al.  Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. , 2005, Arthritis and rheumatism.

[79]  F. Pileggi,et al.  Lipoprotein(a) levels in systemic lupus erythematosus. , 1994, The Journal of rheumatology.

[80]  P. Tugwell,et al.  Endpoints: consensus recommendations from OMERACT IV , 2000, Lupus.

[81]  S. Ho,et al.  High prevalence of asymptomatically poor muscle perfusion of lower extremities measured in systemic lupus erythematosus patients with abnormal myocardial perfusion , 2004, Rheumatology International.

[82]  J. Gómez-Reino,et al.  Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. , 1996, Arthritis and rheumatism.

[83]  D. Boumpas,et al.  Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. , 1994, Kidney international.

[84]  J. Denburg,et al.  Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state [see comments] , 1993 .

[85]  C. Gordon,et al.  Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. , 2005, Best practice & research. Clinical rheumatology.

[86]  M. Petri,et al.  Validity and reliability of lupus activity measures in the routine clinic setting. , 1992, The Journal of rheumatology.

[87]  H. Hashimoto,et al.  Relation between the level of IgG subclasses and infections in patients with systemic lupus erythematosus. , 1988, International archives of allergy and applied immunology.

[88]  H. Chng,et al.  Hepatitis B virus infection in patients with systemic lupus erythematosus. , 1993, Singapore medical journal.

[89]  C. Greenwood,et al.  Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus. , 2006, Arthritis and rheumatism.

[90]  M. Stella,et al.  Lupus nephritis after hepatitis B vaccination: an uncommon complication. , 2007, Clinical nephrology.

[91]  A. Claudy,et al.  Disease activity in systemic lupus erythematosus , 1979, Clinical and experimental dermatology.

[92]  L. Sargeant,et al.  Severity of systemic lupus erythematosus with diffuse proliferative glomerulonephritis and the ineffectiveness of standard pulse intravenous cyclophosphamide therapy in Jamaican patients , 2003, Lupus.

[93]  S. Shinjo,et al.  Chloroquine-induced bull’s eye maculopathy in rheumatoid arthritis: related to disease duration? , 2007, Clinical Rheumatology.

[94]  J. Mikdashi,et al.  Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. , 2004, Rheumatology.

[95]  C. Bombardier,et al.  Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation. , 1994, The Journal of rheumatology.

[96]  F. Destefano,et al.  Epidemiology of autoimmune reactions induced by vaccination. , 2001, Journal of autoimmunity.

[97]  C. Pineau,et al.  Cancer screening in patients with systemic lupus erythematosus. , 2006, The Journal of rheumatology.

[98]  M. Jadoul,et al.  Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome , 2003, Lupus.

[99]  C. Gordon,et al.  Hormonal exposures and breast cancer in a sample of women with systemic lupus erythematosus. , 2004, Rheumatology.

[100]  G. Ruiz-Irastorza,et al.  Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus , 2004, Lupus.

[101]  M. Vilardell‐Tarrés,et al.  Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. , 2002, Rheumatology.

[102]  D. Dunlop,et al.  Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. , 1999, Arthritis and rheumatism.

[103]  R. Martins,et al.  Hepatitis C virus seroprevalence and genotypes in patients with diffuse connective tissue diseases and spondyloarthropathies. , 2005, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[104]  J. Vianna,et al.  Lupus nephritis: the significance of serological tests at the time of biopsy. , 1991, Clinical and experimental rheumatology.

[105]  I. Rosenberg,et al.  Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus , 1996, The Lancet.

[106]  G. Hughes,et al.  High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients. , 2007, Arthritis and rheumatism.

[107]  M. Oppermann,et al.  Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis , 2004, Lupus.

[108]  F Guillemin,et al.  EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees , 2004, Annals of the rheumatic diseases.

[109]  I. Bruce,et al.  Prevention of cardiovascular disease in systemic lupus erythematosus--proposed guidelines for risk factor management. , 2004, Rheumatology.

[110]  W. Mccune,et al.  Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. , 2004, The Journal of rheumatology.

[111]  Á. Balogh,et al.  Bone mineral density, biochemical markers of bone turnover, and hormonal status in men with systemic lupus erythematosus , 2001, Rheumatology International.

[112]  A. Gough,et al.  Screening for hydroxychloroquine retinopathy , 1998, BMJ.

[113]  M. Schulze,et al.  General and abdominal adiposity and risk of death in Europe. , 2008, The New England journal of medicine.

[114]  D. Branch,et al.  Clinical relevance of multiple antibody specificity testing in anti‐phospholipid syndrome and recurrent pregnancy loss , 2008, Clinical and experimental immunology.

[115]  M. Osiri,et al.  The prevalence of dyslipoproteinemia in Thai patients with systemic lupus erythematosus , 2004, Lupus.

[116]  M. Abrahamowicz,et al.  Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. , 1996, Arthritis and rheumatism.

[117]  D. Gladman,et al.  Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. , 2006, The Journal of rheumatology.

[118]  G. Sanges,et al.  Cognitive impairment in systemic lupus erythematosus: a follow-up study , 2000, Journal of Neurology.

[119]  F. Medina,et al.  Measurement of damage in 210 Mexican patients with systemic lupus erythematosus: relationship with disease duration , 1998, Lupus.

[120]  B. Volpe,et al.  Use of computerized assessment to predict neuropsychological functioning and emotional distress in patients with systemic lupus erythematosus. , 2006, Arthritis and rheumatism.

[121]  M. Khamashta,et al.  Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review , 2008, Annals of the rheumatic diseases.

[122]  M. Abrahamowicz,et al.  Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. , 2001, Arthritis and rheumatism.

[123]  R. Cron,et al.  Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. , 2006, Arthritis and rheumatism.

[124]  T. Ruzicka,et al.  Classification of Cutaneous Lupus Erythematosus , 2005 .

[125]  C. Lau,et al.  Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. , 2006, The American journal of medicine.

[126]  S. Achenbach,et al.  Factors associated with coronary artery calcification in young female patients with SLE , 2003, Annals of the rheumatic diseases.

[127]  A. Steinberg,et al.  A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus. , 1979, Arthritis and rheumatism.

[128]  S. Gabriel,et al.  A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus. , 1993, The Journal of rheumatology.

[129]  R. Domsic,et al.  Prevention of cardiovascular disease in patients with rheumatic diseases. , 2006, Best practice & research. Clinical rheumatology.

[130]  J. Reveille,et al.  The Impact of Increased Body Mass Index on Systemic Lupus Erythematosus: Data From LUMINA, a Multiethnic Cohort , 2007, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[131]  Y. Kanakura,et al.  Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies--Co-existence of these antibodies enhances ADP-induced platelet activation in vitro. , 2004, Thrombosis and haemostasis.

[132]  I. Bruce,et al.  Premature atherosclerosis in systemic lupus erythematosus. , 2000, Rheumatic diseases clinics of North America.

[133]  C. Stein,et al.  Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. , 2005, Arthritis and rheumatism.

[134]  K. Chan,et al.  Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. , 2002, Arthritis and rheumatism.

[135]  S. Lertmaharit,et al.  Bone mineral density in premenopausal women with systemic lupus erythematosus. , 2003, The Journal of rheumatology.

[136]  Jeffrey R Curtis,et al.  Population-based assessment of adverse events associated with long-term glucocorticoid use. , 2006, Arthritis and rheumatism.

[137]  Systemic lupus erythematosus in three ethnic groups. X. Measuring cognitive impairment with the cognitive symptoms inventory. , 2002, Arthritis and rheumatism.

[138]  D. Isenberg,et al.  Systemic lupus erythematosus. , 2008, The New England journal of medicine.

[139]  K. Kalunian,et al.  Assessing disease activity in SLE patients during pregnancy , 1999, Lupus.

[140]  C. Gordon,et al.  Prevalence and predictors of fragility fractures in systemic lupus erythematosus , 2004, Annals of the rheumatic diseases.

[141]  D. Buskila,et al.  Specific antibody response after influenza immunization in systemic lupus erythematosus. , 2002, The Journal of rheumatology.

[142]  J. Berden,et al.  Renal immunofluorescence and the prediction of renal outcome in patients with proliferative lupus nephritis , 2000, Lupus.

[143]  M. Petri,et al.  Coronary Artery Disease Risk Factors in the Johns Hopkins Lupus Cohort: Prevalence, Recognition by Patients, and Preventive Practices , 1992, Medicine.

[144]  G. Ujj,et al.  Influenza vaccination and the production of anti‐phospholipid antibodies in patients with systemic lupus erythematosus , 2006, Scandinavian journal of rheumatology.

[145]  R. Sontheimer.  Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. , 2005, Autoimmunity reviews.

[146]  A. Smit,et al.  Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus , 2006, Lupus.

[147]  C. Valdez,et al.  Validating a computerized neuropsychological test battery for mixed ethnic lupus patients , 2003, Lupus.

[148]  D. Isenberg,et al.  Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. , 2000, Rheumatology.

[149]  T. Peto,et al.  Relation between lymphopenia and bacteraemia in UK adults with medical emergencies , 2004, Journal of Clinical Pathology.

[150]  S. Quaglini,et al.  The long-term outcome of 93 patients with proliferative lupus nephritis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[151]  K. Kogure,et al.  [Recurrent aseptic meningitis following influenza vaccination in a case of systemic lupus erythematosus]. , 1983, Rinsho shinkeigaku = Clinical neurology.

[152]  J. Ioannidis,et al.  EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics , 2007, Annals of the rheumatic diseases.

[153]  S. Y. Kim,et al.  Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus , 2001, Lupus.

[154]  E. Yelin,et al.  A quality indicator set for systemic lupus erythematosus. , 2009, Arthritis and rheumatism.

[155]  J. Denburg,et al.  How "soft" are soft neurological signs? The relationship of subjective neuropsychiatric complaints to cognitive function in systemic lupus erythematosus. , 2003, The Journal of rheumatology.

[156]  E. Bonfá,et al.  Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus , 2007, Lupus.

[157]  D. D'cruz,et al.  Acute Viral Infections in Patients With Systemic Lupus Erythematosus: Description of 23 Cases and Review of the Literature , 2008, Medicine.

[158]  A. Barbieri,et al.  Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus , 2003, Annals of the rheumatic diseases.

[159]  W. Mccune,et al.  Prevention of infectious complications in rheumatic disease patients: immunization, Pneumocystis carinii prophylaxis, and screening for latent infections. , 1999, Current opinion in rheumatology.

[160]  E. Bonfá,et al.  Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies , 1997, Lupus.

[161]  K. Costenbader,et al.  Disparities in lupus care and outcomes , 2009, Current opinion in rheumatology.

[162]  D. Gladman,et al.  Clinically active serologically quiescent systemic lupus erythematosus. , 2003, The Journal of rheumatology.

[163]  M. Petri,et al.  Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. , 2006, The Journal of rheumatology.

[164]  L. Sargeant,et al.  The Outcome of Lupus Nephritis in Jamaican Patients , 2007, The American journal of the medical sciences.

[165]  I. Litinsky,et al.  Pneumococcal vaccination of patients with systemic lupus erythematosus: Effects on generation of autoantibodies , 2005, Autoimmunity.

[166]  R. Hoover,et al.  Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[167]  E. Shapiro,et al.  Comment on the article "can immunization precipitate connective tissue disease? Report of 5 cases of systemic lupus erythematosus and review of the literature". , 2000, Seminars in arthritis and rheumatism.

[168]  M. Urowitz,et al.  Osteoporosis in systemic lupus erythematosus: factors associated with referral for bone mineral density studies, prevalence of osteoporosis and factors associated with reduced bone density , 2004, Lupus.

[169]  M. Petri,et al.  Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. , 1991, Arthritis and rheumatism.

[170]  U. Mercado,et al.  Influenza vaccination of patients with systemic lupus erythematosus. , 2004, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[171]  I. Bruce,et al.  Natural history of hypercholesterolemia in systemic lupus erythematosus. , 1999, The Journal of rheumatology.

[172]  J. Schölmerich,et al.  Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. , 2005, The Journal of rheumatology.

[173]  F. Salaffi,et al.  Health-related quality of life in Italian patients with systemic lupus erythematosus , 2004 .

[174]  D. Gladman,et al.  Accurately describing changes in disease activity in Systemic Lupus Erythematosus. , 2000, The Journal of rheumatology.

[175]  D. Gladman,et al.  Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity. , 2000, The Journal of rheumatology.

[176]  C. Kallenberg,et al.  The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long term observation , 1997, Annals of the rheumatic diseases.

[177]  M. Matucci-Cerinic,et al.  Pregnancy outcome in systemic lupus erythematosus complicated by anti-phospholipid antibodies. , 2008, Rheumatology.

[178]  D. Dunlop,et al.  Self-reported fractures and associated factors in women with systemic lupus erythematosus. , 2007, The Journal of rheumatology.

[179]  D. Alarcón-Segovia,et al.  C-reactive protein in the differential diagnosis between infection and disease reactivation in SLE. , 1981, The Journal of rheumatology.

[180]  J. Guisérix,et al.  Systemic lupus erythematosus and thrombocytopenic purpura in two members of the same family following hepatitis B vaccine. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[181]  L. Kuller,et al.  Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. , 2004, Arthritis and rheumatism.

[182]  E. Schned,et al.  Derivation of the SLEDAI. , 1993, Arthritis and rheumatism.

[183]  E. Werle,et al.  Anti-dsDNA antibody subtypes and anti-C1q antibodies: toward a more reliable diagnosis and monitoring of systemic lupus erythematosus and lupus nephritis , 2006, Lupus.

[184]  J. Varga,et al.  Information on diagnosis and management of systemic lupus erythematosus derived from the routine measurement of 8 nuclear autoantibodies. , 2003, The Journal of rheumatology.

[185]  G. Illei,et al.  Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis , 2001, Annals of Internal Medicine.

[186]  I. Bruce,et al.  Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. , 2008, Arthritis and rheumatism.

[187]  K. Leong,et al.  Lipid profiles in patients with systemic lupus erythematosus. , 1994, The Journal of rheumatology.

[188]  D. Isenberg,et al.  Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. , 1996, Annals of the rheumatic diseases.

[189]  L. Magder,et al.  Damage in systemic lupus erythematosus and its association with corticosteroids. , 2000, Arthritis and rheumatism.

[190]  P. Tugwell,et al.  Outcome measures to be used in clinical trials in systemic lupus erythematosus. , 1999, The Journal of rheumatology.

[191]  M. Boyanov,et al.  Bone mineral density changes in women with systemic lupus erythematosus , 2003, Clinical Rheumatology.

[192]  Viral, fungal and mycobacterial infections in patients with systemic lupus erythematosus , 1999 .

[193]  E. Vignon,et al.  Rheumatic disorders developed after hepatitis B vaccination. , 1999, Rheumatology.

[194]  D. Buskila,et al.  Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity. , 2000, The Journal of rheumatology.

[195]  T. Harrer,et al.  Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus , 2002, Annals of the rheumatic diseases.

[196]  F. Formiga,et al.  Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients , 2001, Lupus.

[197]  D. Dunlop,et al.  Disease damage and low bone mineral density: an analysis of women with systemic lupus erythematosus ever and never receiving corticosteroids. , 2006, Rheumatology.

[198]  M. Vilardell‐Tarrés,et al.  Antihistone and anti-double-stranded deoxyribonucleic acid antibodies are associated with renal disease in systemic lupus erythematosus. , 2004, The American journal of medicine.

[199]  M. Inanç,et al.  Tuberculosis in Turkish patients with systemic lupus erythematosus: increased frequency of extrapulmonary localization , 2004, Lupus.

[200]  M. Vilardell,et al.  Contribution of the initial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients , 2003, Annals of the rheumatic diseases.

[201]  M. Petri,et al.  Assessment of systemic lupus erythematosus. , 2005, Clinical and experimental rheumatology.

[202]  S. Bombardieri,et al.  Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. , 2002, Kidney international.

[203]  M. Vilardell‐Tarrés,et al.  Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone , 2003, Lupus.

[204]  J. Mikdashi,et al.  Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus , 2005, Neurology.

[205]  S. Brink,et al.  The relationship of anticardiolipin antibodies to disease activity in systemic lupus erythematosus. , 1989, British journal of rheumatology.

[206]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.

[207]  M. Yaron,et al.  Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[208]  W. Louthrenoo,et al.  Ocular side effects of chloroquine in patients with rheumatoid arthritis, systemic lupus erythematosus and scleroderma. , 2007, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[209]  G. Burmester,et al.  Value of anticardiolipin antibodies for monitoring disease activity in systemic lupus erythematosus and other rheumatic diseases , 1997, Clinical Rheumatology.

[210]  S. Eiam-Ong,et al.  Correlations between antinucleosome antibodies and anti-double-stranded DNA antibodies, C3, C4, and clinical activity in lupus patients. , 2006, Clinical and experimental rheumatology.

[211]  F. Kainberger,et al.  Bone mineral density and biochemical parameters of bone metabolism in female patients with systemic lupus erythematosus , 2000, Annals of the rheumatic diseases.

[212]  J. Sabio,et al.  Risk factors related to hypertension in a Spanish systemic lupus erythematosus cohort , 2001, Lupus.

[213]  H. Poppel,et al.  Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide. , 1998, The Journal of urology.

[214]  S. Yeap,et al.  Dietary calcium and bone mineral density in premenopausal women with systemic lupus erythematosus , 2006, Clinical Rheumatology.

[215]  N. Amino,et al.  Risk of arterial thrombosis in patients with anticardiolipin antibodies and lupus anticoagulant , 1997, British journal of haematology.

[216]  M. Petri,et al.  Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? , 2005, Arthritis and rheumatism.

[217]  G. Weissmann,et al.  C-reactive protein in systemic lupus erythematosus. , 1977, Arthritis and rheumatism.

[218]  M. Ward,et al.  Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. , 2000, The Journal of rheumatology.

[219]  A. Clarke,et al.  Learning from discordance in patient and physician global assessments of systemic lupus erythematosus disease activity. , 2000, The Journal of rheumatology.

[220]  A. Schattner.  Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. , 2005, Vaccine.

[221]  J. Piette,et al.  Factors affecting outcome and prognosis in membranous lupus nephropathy. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[222]  J. Reveille,et al.  Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. , 2005, Rheumatology.

[223]  D. Fong,et al.  Non-tuberculous mycobacterial infection in patients with systemic lupus erythematosus. , 2006, Rheumatology.

[224]  Joni K. Evans,et al.  Severe lupus nephritis: racial differences in presentation and outcome. , 2007, Journal of the American Society of Nephrology : JASN.

[225]  H. Walling,et al.  Cutaneous Lupus Erythematosus , 2009, American journal of clinical dermatology.

[226]  M. Petri.  Monitoring systemic lupus erythematosus in standard clinical care. , 2007, Best practice & research. Clinical rheumatology.

[227]  Joni K. Evans,et al.  Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[228]  C. Orfanos,et al.  Epidemiology and socioeconomic impact of skin disease in lupus erythematosus , 1997, Lupus.

[229]  M. Bernstein,et al.  Lupus erythematosus: systemic and cutaneous manifestations. , 2006, Clinics in dermatology.

[230]  D. Isenberg,et al.  Hodgkin's lymphoma in systemic lupus erythematosus. , 2007, Rheumatology.

[231]  D. Wallace,et al.  Lupus in the 1980s: III. Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center. , 1995, Seminars in arthritis and rheumatism.

[232]  L. Mouthon,et al.  Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus , 2001, Annals of the rheumatic diseases.

[233]  D. Symmons,et al.  Development and Assessment of a Computerized Index of Clinical Disease Activity in Systemic Lupus Erythematosus , 1988 .

[234]  C. Mok,et al.  Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus , 2005, Lupus.

[235]  S. Shankar,et al.  Peripheral vascular disease in systemic lupus erythematosus , 2007, Lupus.

[236]  D. Isenberg,et al.  Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective study. , 2004, Rheumatology.

[237]  M Cutolo,et al.  Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data , 2005, Annals of the rheumatic diseases.

[238]  Á. Balogh,et al.  Bone Mineral Density in Women with Systemic Lupus Erythematosus , 2002, Clinical Rheumatology.

[239]  P. D. de Groot,et al.  Fluctuations of anticardiolipin antibody levels in patients with systemic lupus erythematosus: a prospective study. , 1989, Annals of the rheumatic diseases.

[240]  A. Fraga,et al.  Infections in outpatients with systemic lupus erythematosus: a prospective study , 2001, Lupus.

[241]  P. Tugwell,et al.  Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. , 1999, The Journal of rheumatology.

[242]  D. Gladman,et al.  Lung cancer in systemic lupus erythematosus. , 2007, Lung cancer.

[243]  J. Bach,et al.  Diagnostic value of anti-nucleosome antibodies in the assessment of disease activity of systemic lupus erythematosus: a prospective study comparing anti-nucleosome with anti-dsDNA antibodies. , 2006, The Journal of rheumatology.

[244]  R. Benedict,et al.  Working memory and processing speed deficits in systemic lupus erythematosus as measured by the paced auditory serial addition test , 2004, Journal of the International Neuropsychological Society.

[245]  R. Cervera,et al.  Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. , 2005, Rheumatology.

[246]  G. Tsokos,et al.  Prophylactic use of antibiotics and immunisations in patients with SLE , 2002, Annals of the rheumatic diseases.

[247]  Y. Shoenfeld,et al.  Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. , 2004, Seminars in arthritis and rheumatism.

[248]  D. Isenberg,et al.  An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systemic lupus erythematosus: a cross-sectional study. , 2001, Rheumatology.

[249]  P. Sparén,et al.  Urinary bladder cancer in Wegener’s granulomatosis: risks and relation to cyclophosphamide , 2004, Annals of the rheumatic diseases.

[250]  J. Reveille,et al.  Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage. , 2003, Rheumatology.

[251]  L. Stojanovich.  Influenza Vaccination of Patients With Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA) , 2006, Clinical & developmental immunology.

[252]  Paolo Raggi,et al.  Premature coronary-artery atherosclerosis in systemic lupus erythematosus. , 2003, The New England journal of medicine.

[253]  G. Espinosa,et al.  Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. , 2006, Arthritis and rheumatism.

[254]  C. Kovarik,et al.  The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: expansion for rheumatology and dermatology. , 2008, Arthritis and rheumatism.

[255]  J. Schwartz,et al.  Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. , 2001, The American journal of cardiology.

[256]  K O Kong,et al.  Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). , 2005, Rheumatology.

[257]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[258]  G. Ruiz-Irastorza,et al.  High risk of tuberculosis in systemic lupus erythematosus? , 2006, Lupus.

[259]  P. Raggi,et al.  Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus , 2006, Lupus.

[260]  T. Kasama,et al.  Clinical evaluation of patients with inflammatory connective tissue diseases complicated by cytomegalovirus antigenemia , 2006, Modern rheumatology.

[261]  K. Steinsson,et al.  Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus , 2003, Lupus.

[262]  S. Quaglini,et al.  "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. , 1996, Kidney international.

[263]  S. Jabłońska,et al.  Subacute cutaneous lupus erythematosus versus systemic lupus erythematosus: diagnostic criteria and therapeutic implications. , 1998, Journal of the American Academy of Dermatology.

[264]  J. Berlin,et al.  Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosus , 2004, Lupus.

[265]  V. Werth,et al.  Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus , 2007, Dermatologic therapy.

[266]  P. Limburg,et al.  Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. , 1990, Arthritis and rheumatism.

[267]  I. Bruce,et al.  Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. , 1999, The Journal of rheumatology.

[268]  A. Krieg,et al.  Can immunization precipitate connective tissue disease? Report of five cases of systemic lupus erythematosus and review of the literature. , 1999, Seminars in arthritis and rheumatism.

[269]  S. Bombardieri,et al.  Therapy with pulse methylprednisolone and short course pulse cyclophosphamide for diffuse proliferative glomerulonephritis , 2001, Lupus.

[270]  C. Bombardier,et al.  Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. , 1992, The Journal of rheumatology.

[271]  J. Reveille,et al.  Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. , 2005, Arthritis and rheumatism.

[272]  Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time. , 2006, Annals of the rheumatic diseases.

[273]  P. Woo,et al.  The use of the British Isles Lupus Assessment Group (BILAG) index as a valid tool in assessing disease activity in childhood-onset systemic lupus erythematosus. , 2004, Rheumatology.

[274]  I. Bruce,et al.  Systemic Lupus Erythematosus: An Independent Risk Factor for Endothelial Dysfunction in Women , 2004, Circulation.

[275]  M. Bijl,et al.  Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease , 2005, Annals of the rheumatic diseases.

[276]  J. Janosky,et al.  Risk of malignancy in women with systemic lupus erythematosus. , 1995, The Journal of rheumatology.

[277]  J. Reveille,et al.  Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual. , 2005, The Journal of rheumatology.

[278]  S. West,et al.  Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus. , 2004, Arthritis and rheumatism.

[279]  Hiroshi,et al.  Incidence and clinical features of cytomegalovirus infection diagnosed by cytomegalovirus pp65 antigenemia assay during high dose corticosteroid therapy for collagen vascular diseases. , 2006, Clinical and experimental rheumatology.

[280]  M. Soares,et al.  Rate, pattern and factors related to damage in Brazilian systemic lupus erythematosus patients , 2003, Lupus.

[281]  M. Khamashta,et al.  Malignancy in Systemic Lupus Erythematosus: a Report of Five Cases in a Series of 96 Patients , 1993, Lupus.

[282]  N. Rothfield,et al.  Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. , 2001, The Journal of rheumatology.

[283]  D. Gladman,et al.  An international cohort study of cancer in systemic lupus erythematosus. , 2005, Arthritis and rheumatism.

[284]  A. Drosos,et al.  Systemic Lupus Erythematosus in Greece. Clinical Features, Evolution and Outcome: a Descriptive Analysis of 292 Patients , 1993, Lupus.

[285]  L. Magder,et al.  Predictors of Survival in Systemic Lupus Erythematosus , 2006, Medicine.

[286]  O. Nived,et al.  Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden , 2001, Lupus.

[287]  M. Liang,et al.  Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. , 1989, Arthritis and rheumatism.

[288]  D. Boumpas,et al.  High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[289]  A. Grayzel,et al.  Impaired response to pneumococcal vaccine in systemic lupus erythematosus. , 1980, Arthritis and rheumatism.

[290]  S. Kittner,et al.  Baseline Disease Activity, Hyperlipidemia, and Hypertension Are Predictive Factors for Ischemic Stroke and Stroke Severity in Systemic Lupus Erythematosus , 2007, Stroke.

[291]  G. Haugeberg,et al.  Bone mineral density in systemic lupus erythematosus: comparison with rheumatoid arthritis and healthy controls , 2000, Annals of the rheumatic diseases.

[292]  D. Isenberg,et al.  Systemic Lupus Erythematosus Measures , 2003 .

[293]  M. Abrahamowicz,et al.  Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies? , 1996, The Journal of rheumatology.

[294]  C. Heneghan,et al.  Levels of Evidence , 2006 .

[295]  M. García-Carrasco,et al.  Cardiovascular risk factors and the long-term outcome of lupus nephritis. , 2001, QJM : monthly journal of the Association of Physicians.

[296]  M. Zeher,et al.  Occurrence of Malignancies in Hungarian Patients with Systemic Lupus Erythematosus , 2007, Annals of the New York Academy of Sciences.

[297]  S. Bombardieri,et al.  Prevalence and clinico-serological correlations of anti-alpha-enolase, anti-C1q, and anti-dsDNA antibodies in patients with systemic lupus erythematosus. , 2006, The Journal of rheumatology.

[298]  E. Acevedo-Vásquez,et al.  Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis , 2005, Annals of the rheumatic diseases.

[299]  J. Boivin,et al.  Do traditional Gail model risk factors account for increased breast cancer in women with lupus? , 2003, The Journal of rheumatology.

[300]  G. Guyatt,et al.  Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.

[301]  I. Bruce.  Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin? , 2005, Best practice & research. Clinical rheumatology.

[302]  M. Abrahamowicz,et al.  Impact of disease activity and cumulative damage on the health of lupus patients , 1998, Lupus.

[303]  L. Kuller,et al.  Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. , 1999, Arthritis and rheumatism.

[304]  G. Valesini,et al.  Vaccination and rheumatic diseases: Is there still a dilemma? , 2007 .

[305]  J. Reveille,et al.  African–American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: results from LUMINA, a multiethnic cohort (LUMINAXLV) , 2006, Annals of the rheumatic diseases.

[306]  Joakim Dillner,et al.  Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. , 2008, Vaccine.

[307]  A. Hamsten,et al.  Risk Factors for Cardiovascular Disease in Systemic Lupus Erythematosus , 2001, Circulation.

[308]  V. Werth.  Clinical manifestations of cutaneous lupus erythematosus. , 2005, Autoimmunity reviews.

[309]  M. García-Carrasco,et al.  Hepatitis C virus infection mimicking systemic lupus erythematosus: study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus. , 2000, Arthritis and rheumatism.

[310]  Kenneth G. C. Smith,et al.  European consensus statement on the terminology used in the management of lupus glomerulonephritis , 2009, Lupus.

[311]  P. Meroni,et al.  Updating on the Pathogenic Mechanisms 5 of the Antiphospholipid Antibodies-Associated Pregnancy Loss , 2008, Clinical reviews in allergy & immunology.

[312]  R. Carr,et al.  Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. , 2002, Ophthalmology.

[313]  K. L. Wong.  Pattern of SLE in Hong Kong Chinese: a cohort study. , 1992, Scandinavian journal of rheumatology.

[314]  Y. Levy,et al.  Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. , 2002, Arthritis and rheumatism.

[315]  I. Bruce,et al.  Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. , 2007, Arthritis and rheumatism.

[316]  RD Sontheimer.  The lexicon of cutaneous lupus erythematosus-A review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus , 1997, Lupus.

[317]  I. Bruce,et al.  Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. , 2007, Rheumatology.

[318]  T. Gambichler,et al.  Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy , 2007, The British journal of dermatology.

[319]  T. Witte,et al.  Prognostic parameters for flare in systemic lupus erythematosus. , 2000, Rheumatology.

[320]  C. Briani,et al.  Lupus: improving long-term prognosis , 2008, Lupus.

[321]  J. Stone,et al.  Outcome of renal transplantation in systemic lupus erythematosus. , 1997, Seminars in arthritis and rheumatism.

[322]  J. Nossent,et al.  Systemic lupus erythematosus. II. Observations on the occurrence of exacerbations in the disease course: Dutch experience with 110 patients studied prospectively. , 1989, Annals of the rheumatic diseases.

[323]  M. Schneider,et al.  EULAR-Empfehlungen zur Behandlung des systemischen Lupus erythematodes , 2009, Zeitschrift für Rheumatologie.

[324]  C. Durkin,et al.  Antibodies to cardiolipin in stroke: association with mortality and functional recovery in patients without systemic lupus erythematosus. , 1991, The Quarterly journal of medicine.

[325]  J. Palmer.  Finding the evidence , 1994 .